Ameloblasts secrete amelogenins on the pre-existing enamel matrix glycoprot
eins at the dentine-enamel junction. The hypothesis that amelogenins may in
teract with enamel matrix glycoproteins is tested by hemagglutination of pu
rified, native (porcine) and recombinant murine amelogenins (rM179 and rM16
6) and hemaggIutination inhibition with sugars. Amelogenin agglutination of
murine erythrocytes was specifically inhibited by N-acetylglucosamine (Glc
NAc), chitobiose, and chitotetraose and by ovalbumin with terminal GlcNAc.
The GlcNAc affinity was confirmed by dosimetric binding of rM179 with [C-14
]GlcNAc, specific binding in relation to varying concentrations of GlcNAc,
Scatchard plot analysis and competitive inhibition with Gold GlcNAc, The he
magglutination activity and [C-14]GlcNAc affinity were retained by the NH2-
terminal tyrosine-rich amelogenin peptide (TRAP) but not by the leucine-ric
h amelogenin peptide, LRAP (a polypeptide sharing 33 amino acid residues of
TRAP), or by the C-terminal 13 residue polypeptide of amelogenin (rM179).
Since TRAP but not the 33-residue sequence of the TRAP shared by LRAP bound
to [C-14]GlcNAc, we inferred that the GlcNAc binding motif was located in
the 13-residue tyrosyl C-terminal domain of TRAP (PYPSYGYEPMGGW), which was
absent from LRAP, [C-14]GlcNAc did indeed bind to this '"amelogenin tyrosy
l motif peptide" but not when the tyrosyl residues were substituted with ph
enylalanine or when the third proline was replaced by threonine. Significan
tly, this latter modification mimics a point mutation identified in a case
of human X-linked amelogenesis imperfecta. The amelogenin tyrosyl motif pep
tide sequence showed a similarity to the secondary GlcNAc-binding site of w
heat germ agglutinin.